-
1.发明申请Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase 审中-公开抗体和改进的测试样品处理方法用于髓过氧化物酶的测定公开(公告)号：US20090148866A1
公开(公告)日：2009-06-11
申请号：US12122244
申请日：2008-05-16
申请人： Saul A. Datwyler , David J. Hawksworth , Stephen C. Hsu , Matthew S. Matias , David P. Pacenti , Mary S. Pinkus , Jessie W. Shih , Bryan C. Tieman , Joan D. Tyner , Robert N. Ziemann , Lowell J. Tyner
发明人： Saul A. Datwyler , David J. Hawksworth , Stephen C. Hsu , Matthew S. Matias , David P. Pacenti , Mary S. Pinkus , Jessie W. Shih , Bryan C. Tieman , Joan D. Tyner , Robert N. Ziemann , Lowell J. Tyner
IPC分类号： G01N33/573 , C12N5/06 , C12Q1/28 , C07K16/18
CPC分类号： C12Q1/28 , C07K16/40 , C07K2317/20 , C07K2317/92 , G01N33/573 , G01N33/6893 , G01N2800/50 , G01N2800/56
摘要： The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.
摘要翻译： 本公开涉及可用于测定样品中髓过氧化物酶（MPO）的浓度水平的测定中的分离的抗体。 此外，本公开还涉及在测定中使用改进的测试样品处理方法，以便保留测试样品中的原始MPO水平。
-
公开(公告)号：US20100015637A1
公开(公告)日：2010-01-21
申请号：US12485114
申请日：2009-06-16
申请人： Susan E. Brophy , Lianli Chi , Saul A. Datwyler , David J. Hawksworth , Don M. Laird , Sharmila Manoj , Mary S. Pinkus , Dominick L. Pucci , Carol S. Ramsay , David C. Sogin , Bailin Tu , Joan D. Tyner , Lowell J Tyner , Zhiguang Yu , Robert N. Ziemann
发明人： Susan E. Brophy , Lianli Chi , Saul A. Datwyler , David J. Hawksworth , Don M. Laird , Sharmila Manoj , Mary S. Pinkus , Dominick L. Pucci , Carol S. Ramsay , David C. Sogin , Bailin Tu , Joan D. Tyner , Lowell J Tyner , Zhiguang Yu , Robert N. Ziemann
CPC分类号： C07K16/22 , C07K14/475 , C07K2317/92 , G01N33/74 , G01N2333/475
摘要： The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.
摘要翻译： 本公开涉及糖基化和去糖基化的人PlGF-1，使用糖基化和去糖基化的人PlGF-1的方法，与人PlGF-1结合的抗体，使用抗体和人PlGF-1免疫测定和试剂盒的方法。
-
3.发明申请公开(公告)号：US20080286818A1
公开(公告)日：2008-11-20
申请号：US11750507
申请日：2007-05-18
IPC分类号： G01N33/573 , C12Q1/28
CPC分类号： G01N33/573 , G01N2333/902
摘要： The invention provides a method for determining concentration of myeloperoxidase (MPO) in a human blood sample comprising: (a) providing a human peripheral blood sample stored under MPO preservation conditions; and (b) determining concentration of MPO in a plasma sample derived from the human peripheral blood sample. In a preferred embodiment, the MPO preservation conditions used in the invention comprise storage of the human peripheral blood sample in a plasma collection tube containing a leukocyte MPO secretion inhibitor. In this embodiment, the leukocyte MPO secretion inhibitor is preferably ethylene diamine tetraacetic acid (EDTA). The assays used in the inventive methods can comprise any clinically useful assay for determining MPO plasma concentration, including sandwich and competitive immunoassays, clinical chemistry assays and enzymatic assays.
摘要翻译： 本发明提供了一种测定人血液样品中髓过氧化物酶（MPO）浓度的方法，包括：（a）提供在MPO保存条件下储存的人外周血样品; 和（b）确定衍生自人外周血样品的血浆样品中MPO的浓度。 在优选的实施方案中，用于本发明的MPO保存条件包括将人外周血样品储存在含有白细胞MPO分泌抑制剂的血浆收集管中。 在该实施方式中，白细胞MPO分泌抑制剂优选为乙二胺四乙酸（EDTA）。 用于本发明方法的测定法可以包括用于测定MPO血浆浓度的任何临床有用的测定法，包括夹心和竞争性免疫测定，临床化学测定和酶测定。
-
4.发明授权Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making 失效可溶性FMS样酪氨酸激酶-1（sFLT-1）抗体及相关组成，试剂盒，使用方法，材料及制备方法公开(公告)号：US08349325B2
公开(公告)日：2013-01-08
申请号：US12643847
申请日：2009-12-21
申请人： Susan E. Brophy , Saul A. Datwyler , David J. Hawksworth , Don C. Laird , Sharmila Manoj , Dominick L. Pucci , Bryan C. Tieman , Joan Tyner , Lowell J. Tyner, legal representative , Zhiguang Yu
发明人： Susan E. Brophy , Saul A. Datwyler , David J. Hawksworth , Don C. Laird , Sharmila Manoj , Dominick L. Pucci , Bryan C. Tieman , Joan Tyner , Zhiguang Yu
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2863 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.
摘要翻译： 特异性结合sFlt-1或其片段的分离的抗体，其具有（i）包含SEQ ID NO：2的氨基酸序列的可变重结构域，（ii）包含SEQ ID NO：2的氨基酸序列的可变轻区域区域 SEQ ID NO：4，或（iii）（i）和（ii）两者，药物组合物和包含这种抗体的试剂盒，制备这种抗体的方法，确定sFlt- 1或其片段，治疗或预防性地需要sFlt-1拮抗剂的方法，分离的核酸，其包含编码（i）SEQ ID NO：1的氨基酸序列的核苷酸序列， 2，（ii）SEQ ID NO：4或（iii）（i）和（ii），任选地作为载体的一部分，以及包含并表达这种核酸的宿主细胞。
-
5.发明申请SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING 失效可溶性FMS-样酪氨酸激酶-1（sFLT-1）抗体及相关组合物，试剂盒，使用方法，材料和制备方法公开(公告)号：US20100266575A1
公开(公告)日：2010-10-21
申请号：US12643847
申请日：2009-12-21
申请人： Susan E. Brophy , Saul A. Datwyler , David J. Hawksworth , Don C. Laird , Sharmila Manoj , Dominick L. Pucci , Bryan C. Tieman , Joan Tyner , Lowell J. Tyner , Zhiguang Yu
发明人： Susan E. Brophy , Saul A. Datwyler , David J. Hawksworth , Don C. Laird , Sharmila Manoj , Dominick L. Pucci , Bryan C. Tieman , Joan Tyner , Lowell J. Tyner , Zhiguang Yu
IPC分类号： A61K39/395 , C07K16/40 , G01N33/573 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/00 , A61P9/12
CPC分类号： C07K16/2863 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.
摘要翻译： 特异性结合sFlt-1或其片段的分离的抗体，其具有（i）包含SEQ ID NO：2的氨基酸序列的可变重结构域，（ii）包含SEQ ID NO：2的氨基酸序列的可变轻区域区域 SEQ ID NO：4，或（iii）（i）和（ii）两者，药物组合物和包含这种抗体的试剂盒，制备这种抗体的方法，确定sFlt- 1或其片段，治疗或预防性地需要sFlt-1拮抗剂的方法，分离的核酸，其包含编码（i）SEQ ID NO：1的氨基酸序列的核苷酸序列， 2，（ii）SEQ ID NO：4或（iii）（i）和（ii），任选地作为载体的一部分，以及包含并表达这种核酸的宿主细胞。
-
公开(公告)号：US20100004306A1
公开(公告)日：2010-01-07
申请号：US12486671
申请日：2009-06-17
申请人： Evelyn Mary McKeegan , Saul A. Datwyler , David J. Hawksworth , Don M. Laird , Dominick L. Pucci , David C. Sogin , Joan D. Tyner , Robert N. Ziemann , Peter James Ansell , Ke K. Zhang
发明人： Evelyn Mary McKeegan , Saul A. Datwyler , David J. Hawksworth , Don M. Laird , Dominick L. Pucci , David C. Sogin , Joan D. Tyner , Robert N. Ziemann , Peter James Ansell , Ke K. Zhang
IPC分类号： A61K31/416 , G01N33/566 , A61P35/00
CPC分类号： G01N33/574 , G01N33/94 , G01N2800/52
摘要： The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to PlGF-1 companion diagnostic methods and products.
摘要翻译： 本公开涉及用于确定接受药物治疗的受试者是否已经获得了药物有效血液水平的方法。 此外，本公开还涉及确定倾向于或患有疾病的受试者是否将受益于药物治疗的受试者以及通过监测血管发生生物标志物（例如癌症）的受试者的反应的方法 。 特别地，本公开涉及PlGF-1伴侣诊断方法和产品。
-
7.发明授权Biomarkers for prediction of major adverse cardiac events and uses thereof 有权用于预测主要不良心脏事件的生物标志物及其用途公开(公告)号：US08501420B2
公开(公告)日：2013-08-06
申请号：US12871056
申请日：2010-08-30
IPC分类号： G01N31/00
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2800/324 , G01N2800/50 , G01N2800/60
摘要： The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.
摘要翻译： 本发明涉及生物标志物及其水平的组合，其可以用于例如测定与患者中主要不良心脏事件（MACE）的发生相关的风险。
-
8.发明申请公开(公告)号：US20130288269A1
公开(公告)日：2013-10-31
申请号：US13926647
申请日：2013-06-25
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2800/324 , G01N2800/50 , G01N2800/60
摘要： The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.
摘要翻译： 本发明涉及生物标志物及其水平的组合，其可以用于例如测定与患者中主要不良心脏事件（MACE）的发生相关的风险。
-
9.发明申请公开(公告)号：US20110053179A1
公开(公告)日：2011-03-03
申请号：US12871056
申请日：2010-08-30
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2800/324 , G01N2800/50 , G01N2800/60
摘要： The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.
摘要翻译： 本发明涉及生物标志物及其水平的组合，其可以用于例如测定与患者中主要不良心脏事件（MACE）的发生相关的风险。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.043 秒)
